Exact Mass: 572.4229
Exact Mass Matches: 572.4229
Found 295 metabolites which its exact mass value is equals to given mass value 572.4229,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Pancuronium
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03A - Muscle relaxants, peripherally acting agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant
7,8-Dihydroparasiloxanthin
7,8-Dihydroparasiloxanthin is found in fishes. 7,8-Dihydroparasiloxanthin is a constituent of skin and fin of Japanese catfish (Parasilurus asotus). Constituent of skin and fin of Japanese catfish (Parasilurus asotus). 7,8-Dihydroparasiloxanthin is found in fishes.
(3b,5a,22E,24S)-Stigmasta-7,22,25-trien-3-ol 3-glucoside
(3b,5a,22E,24S)-Stigmasta-7,22,25-trien-3-ol 3-glucoside is found in fruits. (3b,5a,22E,24S)-Stigmasta-7,22,25-trien-3-ol 3-glucoside is a constituent of Cucurbita pepo and Momordica charantia (bitter melon). Constituent of Cucurbita pepo and Momordica charantia (bitter melon). (3b,5a,22E,24S)-Stigmasta-7,22,25-trien-3-ol 3-glucoside is found in fruits.
22-Angeloylbarringtogenol C
22-Angeloylbarringtogenol C is found in tea. 22-Angeloylbarringtogenol C is a constituent of Camellia sinensis var. assamica (Assam tea). Constituent of Camellia sinensis variety assamica (Assam tea). 22-Angeloylbarringtogenol C is found in tea.
5,6-Dihydro-5,6-dihydroxy-y,y-carotene
5,6-Dihydro-5,6-dihydroxy-carotene is a carotenoid found in human fluids. Carotenoids are isoprenoid molecules that are widespread in nature and are typically seen as pigments in fruits, flowers, birds and crustacea. Animals are unable to synthesise carotenoids de novo, and rely upon the diet as a source of these compounds. Over recent years there has been considerable interest in dietary carotenoids with respect to their potential in alleviating age-related diseases in humans. This attention has been mirrored by significant advances in cloning most of the carotenoid genes and in the genetic manipulation of crop plants with the intention of increasing levels in the diet. Studies have shown an inverse relationship between the consumption of certain fruits and vegetables and the risk of epithelial cancer. Since carotenoids are among the micronutrients found in cancer preventive foods, detailed qualitative and quantitative determination of these compounds, particularly in fruits and vegetables and in human plasma, have recently become increasingly important. (PMID: 1416048, 15003396). 5,6-Dihydro-5,6-dihydroxy-carotene is a carotenoid found in human fluids.
3'-N-Acetyl-4'-O-(14-methylpentadecanoyl)fusarochromanone
3-N-Acetyl-4-O-(14-methylpentadecanoyl)fusarochromanone is produced by Fusarium equiseti. Production by Fusarium equiseti
Dmap-ethyl-paf
DG(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0)
DG(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0/0:0)
DG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(10:0/0:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))
DG(10:0/0:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0/10:0)
DG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0/10:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0)
DG(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0/0:0)
DG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(10:0/0:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))
DG(10:0/0:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0/10:0)
DG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0/10:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0)
DG(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0/0:0)
DG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(10:0/0:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))
DG(10:0/0:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0/10:0)
DG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0/10:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0)
DG(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0/0:0)
DG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(10:0/0:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))
DG(10:0/0:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0/10:0)
DG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0/10:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0)
DG(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0/0:0)
DG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(10:0/0:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))
DG(10:0/0:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0/10:0)
DG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0/10:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
(4S,5S,6S,4S,5S,6S)-5,6,5,6-Tetrahydro-beta,beta-carotene-4,4-diol
4beta,9alpha,20-trihydroxy-13alpha-pentadecanoate-1,6-tigliadien-3-one
22-O-(3,3-dimethylacryloyl)-A1-barrigenol|22-O-(3-Methyl-2-butenoyl) -(3beta,15alpha,16alpha,22alpha)-12-Oleanene-3,15,16,22,28-pentol
Barringtogenol B|Barringtogenol B; 3beta,21beta,22alpha,28-Tetrahydroxy-16alpha-angeloyloxy-oleanen-(12)|Barrintogenol B
22-Angeloyl -(3beta,15alpha,16alpha,22alpha)-12-Oleanene-3,15,16,22,28-pentol|Olean-12-en-3beta,15alpha,16alpha,22alpha,28-pentol-22-angelat
germanicol trans-coumaroyl ester|olean-18-en-3beta-O-(E)-coumaroyl ester
24beta-ethylcholesta-5,9(11),22E-trien 3-O--beta-D-glucoside|elaeagnoside
7alpha-n-pentadecanoyloxy-6beta,12-dihydroxy-abieta-8,12-diene-11,14-dione
Dihydroparasiloxanthin/ 7,8,7,8-Tetrahydrozeaxanthin
22-Angeloylbarringtogenol C
(3b,5a,22E,24S)-Stigmasta-7,22,25-trien-3-ol 3-glucoside
7,8-Dihydroparasiloxanthin
3'-N-Acetyl-4'-O-(14-methylpentadecanoyl)fusarochromanone
DG(13:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)[iso2]
IC202A
A N-oxide isolated from Streptoalloteichus sp.1454-19. It is a siderophore which exhibits immunosuppressive activity on a mixed lymphocyte culture reaction (MLCR).
Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate
azacyclotridecan-2-one,azepan-2-one,hexane-1,6-diamine,hexanedioic acid
(2Z)-2-(Hydroxymethylene)-3-oxoolean-12-en-28-oic acid phenylmethyl ester
[(1S,4S,5R,6R)-6-(hydroxymethyl)-2,5-dimethyl-4-[(1E,3E)-2-methyl-4-(2,6,6-trimethylcyclohexen-1-yl)buta-1,3-dienyl]-5-[(1E,3E,5E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hexa-1,3,5-trienyl]cyclohex-2-en-1-yl]methanol
2-[4-(dimethylamino)-3-oxo-4H-pyridin-1-ium-1-yl]ethyl (2-ethoxy-3-hexadecoxypropyl) phosphite
Pancuronium
Pancuronium is only found in individuals that have used or taken this drug. It is a bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.
Dihydroparasiloxanthin/7,8,7,8-Tetrahydrozeaxanthin
acetic acid [(3S,5S,9S,14S)-17-acetyloxy-10,13-dimethyl-2,16-bis(1-methyl-1-piperidin-1-iumyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] ester
[(1S,2R,3R,5R,7R,10S,11R,14R,15S)-15-[(3S,5R)-5-[(2S)-3,3-dimethyloxiran-2-yl]-2-hydroxyoxolan-3-yl]-3-hydroxy-2,6,6,10-tetramethyl-7-pentacyclo[12.3.1.01,14.02,11.05,10]octadecanyl] 3-methylbutanoate
(1R,15R,17S)-17-ethyl-6-[(1R,14R,15E)-15-ethylidene-17,18-dimethyl-10,17-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8-tetraen-12-yl]-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene
[(E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxynon-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-3-hydroxy-2-(octanoylamino)heptadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-2-(heptanoylamino)-3-hydroxyoctadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxynonyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-3-hydroxy-2-(nonanoylamino)hexadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-2-acetamido-3-hydroxytricosa-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-2-(butanoylamino)-3-hydroxyhenicosa-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-3-hydroxy-2-(propanoylamino)docosa-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-3-hydroxy-2-(pentanoylamino)icosa-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-2-(hexanoylamino)-3-hydroxynonadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]dodeca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-2-(decanoylamino)-3-hydroxypentadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)tetradeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[(E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxyoct-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-tetraconta-10,13,16,19,22,25,28,31,34,37-decaenoic acid
(1-hydroxy-3-pentadecanoyloxypropan-2-yl) (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
(1-hydroxy-3-tridecanoyloxypropan-2-yl) (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-hydroxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
(1-hydroxy-3-undecanoyloxypropan-2-yl) (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
[1-hydroxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-hydroxypropyl] (Z)-heptadec-9-enoate
[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-hydroxypropyl] (9Z,12Z)-heptadeca-9,12-dienoate
(1-hydroxy-3-nonanoyloxypropan-2-yl) (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate
[1-Carboxy-3-(2-decanoyloxy-3-dodecanoyloxypropoxy)propyl]-trimethylazanium
[1-Carboxy-3-[2,3-di(undecanoyloxy)propoxy]propyl]-trimethylazanium
[1-Carboxy-3-(3-decanoyloxy-2-dodecanoyloxypropoxy)propyl]-trimethylazanium
[(2S)-1-hydroxy-3-tridecanoyloxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate
[(2S)-1-hydroxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate
[(2S)-3-hydroxy-2-tridecanoyloxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate
[(2S)-1-hydroxy-3-undecanoyloxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate
[1-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-hydroxypropan-2-yl] (E)-heptadec-7-enoate
[(2S)-3-hydroxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate
[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-hydroxypropan-2-yl] heptadecanoate
[1-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-hydroxypropan-2-yl] (8E,11E,14E)-heptadeca-8,11,14-trienoate
[(2S)-3-hydroxy-2-undecanoyloxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate
[1-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-hydroxypropan-2-yl] (11E,14E)-heptadeca-11,14-dienoate
[1-Carboxy-3-(3-heptanoyloxy-2-pentadecanoyloxypropoxy)propyl]-trimethylazanium
[3-(3-Acetyloxy-2-icosanoyloxypropoxy)-1-carboxypropyl]-trimethylazanium
[3-(3-Butanoyloxy-2-octadecanoyloxypropoxy)-1-carboxypropyl]-trimethylazanium
[1-Carboxy-3-(3-octanoyloxy-2-tetradecanoyloxypropoxy)propyl]-trimethylazanium
[1-Carboxy-3-(3-nonanoyloxy-2-tridecanoyloxypropoxy)propyl]-trimethylazanium
[1-Carboxy-3-(2-nonadecanoyloxy-3-propanoyloxypropoxy)propyl]-trimethylazanium
[1-Carboxy-3-(2-heptadecanoyloxy-3-pentanoyloxypropoxy)propyl]-trimethylazanium
[1-Carboxy-3-(2-hexadecanoyloxy-3-hexanoyloxypropoxy)propyl]-trimethylazanium
2-[carboxy-[3-[(Z)-docos-13-enoyl]oxy-2-hydroxypropoxy]methoxy]ethyl-trimethylazanium
2-[carboxy-[3-octanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]methoxy]ethyl-trimethylazanium
Pancuronium
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents M - Musculo-skeletal system > M03 - Muscle relaxants > M03A - Muscle relaxants, peripherally acting agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant
3-N-Acetyl-4-O-(14-methylpentadecanoyl)fusarochromanone
N-(5-aminopentyl)-N-(5-{[4-({5-[butylidene(oxido)-lambda(5)-azanyl]pentyl}amino)-4-oxobutanoyl](hydroxy)amino}pentyl)-N-hydroxybutanediamide
1-tridecanoyl-2-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-sn-glycerol
(3s,4ar,6ar,6bs,8ar,12ar,14ar,14br)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl (2z)-3-(4-hydroxyphenyl)prop-2-enoate
1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl pentadecanoate
n-{5-[(3-{[5-({3-[(5-aminopentyl)(hydroxy)carbamoyl]-1-hydroxypropylidene}amino)pentyl](hydroxy)carbamoyl}-1-hydroxypropylidene)amino]pentyl}butanimine oxide
(2r,3r,4s,5s,6r)-2-{[(1r,3as,3bs,7s,9ar,9bs,11ar)-1-[(2r,3e,5s)-5-ethyl-6-methylhepta-3,6-dien-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(3r,4ar,6ar,8ar,12ar,12bs,14ar,14br)-4,4,6a,8a,11,11,12b,14b-octamethyl-1,2,3,4a,5,6,8,9,10,12,12a,13,14,14a-tetradecahydropicen-3-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
2-[(1s,2s,3s,5s)-2,3-dihydroxy-5-(hydroxymethyl)cyclohexyl]-3-hydroxy-5-[(2s,3s,4e,6e,8r,9z,12s)-3-hydroxy-6,8,10,12-tetramethyloctadeca-4,6,9-trien-2-yl]cyclohexa-2,4-dien-1-one
(1s,2s,3s)-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(1r,5s,6s)-5-hydroxy-2,2,6-trimethylcyclohexyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-2,4,4-trimethylcyclohexan-1-ol
(3s,4ar,6ar,8ar,12ar,12bs,14ar,14br)-4,4,6a,8a,11,11,12b,14b-octamethyl-1,2,3,4a,5,6,8,9,10,12,12a,13,14,14a-tetradecahydropicen-3-yl (2z)-3-(4-hydroxyphenyl)prop-2-enoate
(1s,2r,3r,5s,7s,10s,11r,14r,15s)-15-[(2r,3s,5r)-5-[(2s)-3,3-dimethyloxiran-2-yl]-2-hydroxyoxolan-3-yl]-3-hydroxy-2,6,6,10-tetramethylpentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-7-yl 3-methylbutanoate
(4as,9s,10s,10as)-6,10-dihydroxy-7-isopropyl-1,1,4a-trimethyl-5,8-dioxo-2,3,4,9,10,10a-hexahydrophenanthren-9-yl pentadecanoate
(1r)-4-[(3e,5e,7e,9e,11e,13e,15e)-18-[(4r)-4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15-heptaen-1-yl]-3,5,5-trimethylcyclohex-3-en-1-ol
{3-[(16r,17r)-16,17-dihydroxypentacosyl]-5-hydroxyphenyl}oxidanesulfonic acid
[3-(16,17-dihydroxypentacosyl)-5-hydroxyphenyl]oxidanesulfonic acid
22-o-angeloyl theasapogenol b
{"Ingredient_id": "HBIN003746","Ingredient_name": "22-o-angeloyl theasapogenol b","Alias": "NA","Ingredient_formula": "C35H56O6","Ingredient_Smile": "CC=C(C)C(=O)OC1C(C(CC2C1(C(CC3(C2=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C)O)CO)(C)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1236","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
3-o-(e)-coumaroyl-β-amyrin
{"Ingredient_id": "HBIN009318","Ingredient_name": "3-o-(e)-coumaroyl-\u03b2-amyrin","Alias": "NA","Ingredient_formula": "C39H56O3","Ingredient_Smile": "CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC(=O)C=CC6=CC=C(C=C6)O)C)C)C2C1)C)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4149","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
3-o-(z)-coumaroyl-β-amyrin
{"Ingredient_id": "HBIN009443","Ingredient_name": "3-o-(z)-coumaroyl-\u03b2-amyrin","Alias": "NA","Ingredient_formula": "C39H56O3","Ingredient_Smile": "CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC(=O)C=CC6=CC=C(C=C6)O)C)C)C2C1)C)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4150","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
3-(z)-coumaroyllupeol
{"Ingredient_id": "HBIN009770","Ingredient_name": "3-(z)-coumaroyllupeol","Alias": "NA","Ingredient_formula": "C39H56O3","Ingredient_Smile": "CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)OC(=O)C=CC6=CC=C(C=C6)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4168","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
